Skip to main content
. 2021 Feb 3;10(4):566. doi: 10.3390/jcm10040566

Figure 4.

Figure 4

Overview of STAT3 activation via the JAK-STAT pathway (cytokine and growth factor receptor stimulation) and cytoplasmic Src kinase. A JAK inhibitor (ruxolitinib), STAT3 inhibitors (danvatirsen, napabucasin) and a Src inhibitor (dasatinib) are currently in clinical trials for pancreatic cancer.